Identifiability of Biologicals in Adverse Drug Reaction Reports Received From European Clinical Practice-Reference-Cited by-同舟云学术

Identifiability of Biologicals in Adverse Drug Reaction Reports Received From European Clinical Practice

Published:2019-01-11 Issue:4 Volume:105 Page:962-969
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Vermeer Niels S.¹,Giezen Thijs J.²,Zastavnik Sofia³,Wolff‐Holz Elena⁴,Hidalgo‐Simon Ana³

Affiliation:

1. Erasmus MC, University Medical Center RotterdamDepartment of Hospital Pharmacy Rotterdam the Netherlands

2. Foundation Pharmacy for Hospitals in Haarlem Haarlem the Netherlands

3. European Medicines Agency (EMA) London UK

4. Paul‐Ehrlich‐Institut (PEI) Langen Germany

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.1310

Reference35 articles.

1. Pharmacovigilance of Biopharmaceuticals

2. Detection, verification, and quantification of adverse drug reactions

3. Traceability of biologicals: present challenges in pharmacovigilance

4. European Medicines Agency.Guideline on good pharmacovigilance practices (GVP). Product‐ or population‐specific considerations II: biological medicinal products. (EMA/168402/2014 Corr.). (2016). Accessed September 28 2018.

5. European Medicines Agency (EMA).Corporate website. . Accessed September 28 2018.

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacovigilance System in EU;Pharmacovigilance Essentials;2024

2. Future Evolution of Biosimilar Development by Application of Current Science and Available Evidence: The Developer’s Perspective;BioDrugs;2023-08-05

3. Patterns of adverse drug reactions in Jordan: a retrospective analysis of the National Pharmacovigilance Data Registry (2015–2021);Expert Opinion on Drug Safety;2023-06-13

4. A Data Driven Approach to Support Tailored Clinical Programs for Biosimilar Monoclonal Antibodies;Clinical Pharmacology & Therapeutics;2022-12-22

5. The Global Landscape of Manufacturers of Follow-on Biologics: An Overview of Five Major Biosimilar Markets and 15 Countries;BioDrugs;2022-12-06